GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indications are for add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype who are inadequately controlled on medium to high dose corticosteroids plus another asthma controller and also as an add-on treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces EMA to review the regulatory application of Shingrix
- GSK, Oxford to establish GSK-Oxford Cancer Immuno-Prevention Programme
- GSK Pharma call volume above normal and directionally bullish
- GSK’s Jemperli Gains Expanded EU Approval for Endometrial Cancer
- GSK announces expanded EU approval in endometrial cancer for Jemperli combo